The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
Open accessAbstract
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing. Viral sequencing revealed variants of likely clinical importance, including E484K in 1 woman and three mutations (T95I, del142-144, and D614G) in both. These observations indicate a potential risk of illness after successful vaccination and subsequent infection with variant virus, and they provide support for continued efforts to prevent and diagnose infection and to characterize variants in vaccinated persons. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, breakthrough infections have emerged in a small percentage of vaccine recipients, a phenomenon that has been described in other countries and health care institutions.6-8”
From Covid-19 Breakthrough Infections in Vaccinated Health Care Workers (2021) · cites this paper as [8]
In the citing paper
“In contrast, reports in which certain variants of concern were more prevalent in breakthrough infections have been published as well.8,16,26”
From Covid-19 Breakthrough Infections in Vaccinated Health Care Workers (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Self-citationEvolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Self-citationmRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Self-citationEscape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
Self-citationSARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesPreprint
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · bioRxiv · doi:10.1101/2020.06.08.140871 · Cited by 600
Self-citationMeasuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Self-citationmRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557
Cited by
Sorted by citations
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590
Diagnostics for COVID-19: moving from pandemic response to control
Peeling, R. W. W., Heymann, D. L., Teo, Y.-Y., & Garcia, P. J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02346-1 · Cited by 509
Mohammed, I., Nauman, A., Paul, P., Ganesan, S., Chen, K.-H., Jalil, S. M. S., Jaouni, S. H., Kawas, H., Khan, W. A., Vattoth, A. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2027160 · Cited by 406
Human genetic and immunological determinants of critical COVID-19 pneumonia
Zhang, Q., Bastard, P., Effort, C. H. G., Karbuz, A., Gervais, A., Tayoun, A. N. A., Aiuti, A., Bélot, A., Bolze, A., Gaudet, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04447-0 · Cited by 377
SARS-CoV-2 variants of concern are emerging in India
Singh, J., Rahman, S. A., Ehtesham, N. Z., Hira, S., & Hasnain, S. E. (2021) · Nature Medicine · doi:10.1038/s41591-021-01397-4 · Cited by 352
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
Cho, A., Muecksch, F., Schaefer-Babajew, D. J., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · Nature · doi:10.1038/s41586-021-04060-7 · Cited by 263
Self-citationTaquet, M., Dercon, Q., & Harrison, P. J. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.04.013 · Cited by 246
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Hwang, Y., Lu, R., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 247
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
Kimura, I., Kosugi, Y., Wu, J., Zahradník, J., Yamasoba, D., Butlertanaka, E. P., Tanaka, Y., Uriu, K., Liu, Y., Morizako, N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110218 · Cited by 215
Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.-A., Kaneda, A., Nakagawa, S., & Sato, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2114706 · Cited by 214
Lapuente, D., Fuchs, J., Willar, J., Antão, A. V., Eberlein, V., Uhlig, N., Issmail, L., Schmidt, A. P., Oltmanns, F., Peter, A. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27063-4 · Cited by 218
Zhang, T., Deng, R., Wang, Y., Wu, C., Zhang, K., Wang, C., Gong, N., Ledesma‐Amaro, R., Teng, X., Yang, C., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00907-0 · Cited by 215
Enhancement of CRISPR/Cas12a trans -cleavage activity using hairpin DNA reporters
Rossetti, M., Merlo, R., Bagheri, N., Moscone, D., Valenti, A., Saha, A., Arantes, P. R., Ippodrino, R., Ricci, F., Treglia, I., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac578 · Cited by 186
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance
Tegally, H., San, J. E., Cotten, M. L., Moir, M., Tegomoh, B., Mboowa, G., Martin, D. P., Baxter, C., Lambisia, A. W., Diallo, A. B., et al. (2022) · Science · doi:10.1126/science.abq5358 · Cited by 190
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 172
Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants
Esper, F. P., Adhikari, T. M., Tu, Z. J., Cheng, Y., El-Haddad, K., Farkas, D. H., Bosler, D. S., Rhoads, D. D., Procop, G. W., Ko, J. S., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac411 · Cited by 154
Adaptive Immune Responses and Immunity to SARS-CoV-2
Primorac, D., Vrdoljak, K., Brlek, P., Pavelić, E., Molnar, V., Matišić, V., Ivkošić, I. E., & Parčina, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848582 · Cited by 162
Mutation Rates, Mutation Frequencies, and Proofreading-Repair Activities in RNA Virus Genetics
Domingo, E., García‐Crespo, C., Lobo-Vega, R., & Perales, C. (2021) · Viruses · doi:10.3390/v13091882 · Cited by 161
Molnupiravir and Its Antiviral Activity Against COVID-19
Tian, L., Pang, Z., Li, M., Lou, F., An, X., Zhu, S., Song, L., Tong, Y., Fan, H., & Fan, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.855496 · Cited by 157
Tyagi, K., Ghosh, A., Nair, D., Dutta, K., Singh Bhandari, P., Ahmed Ansari, I., & Misra, A. (2021) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.05.001 · Cited by 145
COVID‐19 vaccinations: The unknowns, challenges, and hopes
Mohamed, K., Rzymski, P., Islam, M. S., Makuku, R., Mushtaq, A., Khan, A., Ivanovska, M., Makka, S. A., Hashem, F., Marquez, L. P., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27487 · Cited by 151
Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139
Bayart, J., Douxfils, J., Gillot, C., David, C., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Gérin, V., et al. (2021) · Vaccines · doi:10.3390/vaccines9101092 · Cited by 133
Sokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.09.011 · Cited by 135
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 123
Christensen, P. A., Olsen, R. J., Long, S. W., Subedi, S., Davis, J. J., Hodjat, P., Walley, D. R., Kinskey, J. C., Saavedra, M. O., Pruitt, L., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.10.019 · Cited by 129
Wang, L., Wang, Q., Davis, P. B., Volkow, N. D., & Xu, R. (2021) · World Psychiatry · doi:10.1002/wps.20921 · Cited by 129
Langel, S. N., Johnson, S., Martinez, C. I., Tedjakusuma, S. N., Peinovich, N., Dora, E. G., Kuehl, P. J., Irshad, H., Barrett, E. G., Werts, A. D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6868 · Cited by 121
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Geers, D., Schmitz, K. S., Garrido, H. M. G., Koopmans, M., Dalm, V. A. S. H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116747 · Cited by 127
Katikireddi, S. V., Cerqueira-Silva, T., Vasileiou, E., Robertson, C., Amele, S., Pan, J., Taylor, B., Boaventura, V., Werneck, G. L., Flores-Ortiz, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02754-9 · Cited by 124
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K., Wang, H., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103904 · Cited by 122
Hollow Nanomaterials in Advanced Drug Delivery Systems: From Single‐ to Multiple Shells
Li, Z., Xu, K., Qin, L., Zhao, D., Yang, N., Wang, D., & Yang, Y. (2022) · Advanced Materials · doi:10.1002/adma.202203890 · Cited by 126
Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery
Feng, C., Shi, J., Fan, Q., Wang, Y., Huang, H., Chen, F., Tang, G., Li, Y., Li, P., Li, J. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25312-0 · Cited by 120
To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination
Chiu, N., Chi, H., Tu, Y., Huang, Y.-N., Tai, Y., Weng, S.-L., Chang, L., Huang, D. T., Huang, F.-Y., & Lin, C. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1971522 · Cited by 117
Caniels, T. G., Bontjer, I., van der Straten, K., Poniman, M., Burger, J. A., Appelman, B., Lavell, A. H. A., Oomen, M., Godeke, G.-J., Valle, C., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5365 · Cited by 107
Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity
Aguilar-Bretones, M., Fouchier, R. A. M., Koopmans, M., & van Nierop, G. P. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162192 · Cited by 108
Yang, Y., Yang, M., Peng, Y., Liang, Y., Wei, J., Xing, L., Guo, L., Li, X., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 111
Sexual dimorphism in COVID-19: potential clinical and public health implications
Bechmann, N., Barthel, A., Schedl, A., Herzig, S., Varga, Z., Gebhard, C., Mayr, M., Hantel, C., Beuschlein, F., Wolfrum, C., et al. (2022) · Publikationen an der Universität Bielefeld (Universität Bielefeld) · Cited by 110
Recent developments in the immunopathology of COVID ‐19
Zhang, H., Sun, Y., Wang, Y., Yazıcı, D., Azkur, D., Öğülür, İ., Azkur, A. K., Yang, Z., Chen, X., Zhang, A., et al. (2022) · Allergy · doi:10.1111/all.15593 · Cited by 115
Sexual dimorphism in COVID-19: potential clinical and public health implications
Bechmann, N., Barthel, A., Schedl, A., Herzig, S., Varga, Z., Gebhard, C., Mayr, M., Hantel, C., Beuschlein, F., Wolfrum, C., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00346-6 · Cited by 123
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Abulsoud, A. I., El‐Husseiny, H. M., El-Husseiny, A. A., El‐Mahdy, H. A., Ismail, A., Elkhawaga, S. Y., Khidr, E. G., Fathi, D., Mady, E. A., Najda, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113977 · Cited by 112
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 111
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
Chavda, V. P., Bezbaruah, R., Deka, K., Nongrang, L., & Kalita, T. (2022) · Vaccines · doi:10.3390/vaccines10111926 · Cited by 108
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Grobben, M., van der Straten, K., Brouwer, P. J. M., Brinkkemper, M., Maisonnasse, P., Dereuddre‐Bosquet, N., Appelman, B., Lavell, A. H. A., van Vught, L. A., Burger, J. A., et al. (2021) · eLife · doi:10.7554/elife.70330 · Cited by 103
The COVID-19 Pandemic: a Threat to Antimicrobial Resistance Containment
Founou, R. C., Blocker, A., Noubom, M., Tsayem, C., Choukem, S. P., van Dongen, M. B. M., & Founou, L. L. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0012 · Cited by 108
Gupta, N., Kaur, H., Yadav, P., Mukhopadhyay, L., Sahay, R., Kumar, A., Nyayanit, D. A., Shete, A., Patil, S., Majumdar, T., et al. (2021) · Viruses · doi:10.3390/v13091782 · Cited by 67
Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination
Butt, A. A., Nafady-Hego, H., Chemaitelly, H., Abou-Samra, A.-B., Khal, A. A., Coyle, P. V., Kanaani, Z. A., Kaleeckal, A. H., Latif, A. N., Masalmani, Y. A., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.08.008 · Cited by 94
Immune recall improves antibody durability and breadth to SARS-CoV-2 variants
Chen, Y., Tong, P., Whiteman, N. B., Moghaddam, A. S., Zarghami, M., Zuiani, A., Habibi, S., Gautam, A. K., Keerti, K., Bi, C., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8328 · Cited by 89
Coburn, S. B., Humes, E., Lang, R., Stewart, C., Hogan, B., Gebo, K. A., Napravnik, S., Edwards, J. K., Browne, L., Park, L. S., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.15934 · Cited by 93
Current and Emerging Knowledge in COVID-19
Jeong, Y. J., Wi, Y. M., Park, H., Lee, J. E., Kim, S., & Lee, K. S. (2023) · Radiology · doi:10.1148/radiol.222462 · Cited by 97
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 92
Distinctive features of severe SARS-CoV-2 pneumonia
Budinger, G. R. S., Misharin, A. V., Ridge, K. M., Singer, B. D., & Wunderink, R. G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149412 · Cited by 87
Development of mRNA vaccines against respiratory syncytial virus (RSV)
Qiu, X., Xu, S., Lu, Y., Luo, Z., Yan, Y., Wang, C., & Ji, J. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.10.001 · Cited by 86
Jin, L., Li, Z., Zhang, X., Li, J., & Zhu, F. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2096970 · Cited by 83
Koerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 75
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
Rana, K., Mohindra, R., & Pinnaka, L. V. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107808 · Cited by 77
Veleri, S. (2021) · Experimental Brain Research · doi:10.1007/s00221-021-06244-z · Cited by 77
COVID-19 Mechanisms in the Human Body—What We Know So Far
Kumar, A., Narayan, R. K., Prasoon, P., Kumari, C., Kaur, G., Kumar, S., Kulandhasamy, M., Sesham, K., Pareek, V., Faiq, M. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693938 · Cited by 76
Hatmal, M. M., Al-Hatamleh, M. A. I., Olaimat, A. N., Mohamud, R., Fawaz, M. A., Kateeb, E. T., Alkhairy, O. K., Tayyem, R., Lounis, M., Al‐Raeei, M., et al. (2022) · Vaccines · doi:10.3390/vaccines10030366 · Cited by 73
Liu, C., Lee, J., Ta, C., Soroush, A., Rogers, J. R., Kim, J. H., Natarajan, K., Zucker, J. E., Perl, Y., & Weng, C. (2022) · JMIR Public Health and Surveillance · doi:10.2196/35311 · Cited by 69
BNT162b2 COVID-19 Vaccine Hesitancy among Parents of 4023 Young Adolescents (12–15 Years) in Qatar
Musa, S., Dergaa, I., Abdulmalik, M., Ammar, A., Chamari, K., & Saad, H. B. (2021) · Vaccines · doi:10.3390/vaccines9090981 · Cited by 71
SARS-CoV-2 variants, immune escape, and countermeasures
Zhang, Y., Zhang, H. C., & Zhang, W. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0906-x · Cited by 72
Zhang, B., Shuai, H., Gong, H., Hu, J., Yan, B., Yuen, T. T., Hu, Y., Yoon, C., Wang, X., Hou, Y., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157393 · Cited by 67
A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant
Zhang, M., Liang, Y., Yu, D., Du, B., Cheng, W., Li, L., Yu, Z., Luo, S., Zhang, Y., Wang, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68973 · Cited by 70
Imaging and Clinical Features of COVID-19 Breakthrough Infections: A Multicenter Study
Lee, J. E., Hwang, M., Kim, Y., Chung, M. J., Sim, B. H., Chae, K. J., Yoo, J. Y., & Jeong, Y. J. (2022) · Radiology · doi:10.1148/radiol.213072 · Cited by 67
Wuertz, K. M., Barkei, E. K., Chen, W., Martinez, E. J., Lakhal-Naouar, I., Jagodzinski, L. L., Paquin‐Proulx, D., Gromowski, G. D., Swafford, I., Ganesh, A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00392-7 · Cited by 66
Recent Advances in Antiviral Activities of Triterpenoids
Liu, Y., Yang, L., Wang, H., & Xiong, Y. (2022) · Pharmaceuticals · doi:10.3390/ph15101169 · Cited by 65
SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19
Ravichandran, S., Tang, J., Grubbs, G., Lee, Y., Pourhashemi, S., Hussaini, L., Lapp, S. A., Jerris, R. C., Singh, V., Chahroudi, A., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01051-8 · Cited by 60
Duarte, L. F., Gálvez, N. M. S., Iturriaga, C., Melo-González, F., Soto, J. A., Schultz, B. M., Urzua, M. D., González, L. A., Vázquez, Y., Ríos, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742914 · Cited by 61
Zhou, W., Jiang, L., Liao, S., Wu, F., Yang, G., Hou, L., Liu, L., Pan, X., Jia, W. W.-G., & Zhang, Y. (2023) · Viruses · doi:10.3390/v15081760 · Cited by 64
Cairns, D. M., Dulko, D., Griffiths, J. K., Golan, Y., Cohen, T., Trinquart, L., Price, L. L., Beaulac, K. R., & Selker, H. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.44942 · Cited by 58
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis
John, B. V., Deng, Y., Schwartz, K. B., Taddei, T. H., Kaplan, D. E., Martin, P. B., Chao, H., & Dahman, B. A. (2022) · Hepatology · doi:10.1002/hep.32337 · Cited by 56
Trained Immunity: An Overview and the Impact on COVID-19
Brueggeman, J., Zhao, J., Schank, M., Yao, Z. Q., & Moorman, J. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837524 · Cited by 58
Rénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 62
Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
Gupta, D., Sharma, P., Singh, M., Kumar, M., Ethayathulla, A. S., & Kaur, P. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04008-0 · Cited by 56
Murphy, H. L., & Ly, H. (2021) · Virulence · doi:10.1080/21505594.2021.1996519 · Cited by 54
Emerging SARS-CoV-2 Variants Can Potentially Break Set Epidemiological Barriers in COVID-19
Kumar, A., Parashar, R., Kumar, S., Faiq, M. A., Kumari, C., Kulandhasamy, M., Narayan, R. K., Jha, R. K., Singh, H. N., Prasoon, P., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27467 · Cited by 53
The global succinylation of SARS-CoV-2–infected host cells reveals drug targets
Liu, Q., Wang, H., Zhang, H., Sui, L., Li, L., Xu, W., Du, S., Hao, P., Jiang, Y., Chen, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123065119 · Cited by 53
Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., Lighter, J., Elbel, B. D., Troxel, A. B., & Heguy, A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152702 · Cited by 53
SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways
Mekonnen, D. S., Mengist, H. M., & Jin, T. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1991794 · Cited by 55
Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India
Behera, P., Singh, A. K., Subba, S. H., Arjun, M. C., Sahu, D. P., Chandanshive, P. D., Pradhan, S. K., Parida, S. P., Mishra, A., Patro, B. K., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2034456 · Cited by 51
Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers
Alishaq, M., Nafady‐Hego, H., Jeremijenko, A. M., Ajmi, J. A. A., Elgendy, M., Vinoy, S., Fareh, S. B., Plaatjies, J. V., Nooh, M., Alanzi, N., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258820 · Cited by 50
Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters
Burckhardt, R. M., Dennehy, J. J., Poon, L. L. M., Saif, L. J., & Enquist, L. W. (2021) · Journal of Virology · doi:10.1128/jvi.01973-21 · Cited by 52
Ahmad, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742167 · Cited by 46
McEwen, A. E., Cohen, S., Bryson‐Cahn, C., Liu, C., Pergam, S. A., Lynch, J. B., Schippers, A., Strand, K., Whimbey, E. E., Mani, N. S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab581 · Cited by 51
Upadhyay, V., Lucas, A., Panja, S., Miyauchi, R., & Mallela, K. M. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101208 · Cited by 44
Yang, W.-T., Huang, W.-H., Liao, T.-L., Hsiao, T.-H., Chuang, H.-N., & Liu, P.-Y. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s344099 · Cited by 51
Yan, C., Law, M., Nguyen, S., Cheung, J., & Kong, J. D. (2021) · Journal of Medical Internet Research · doi:10.2196/32685 · Cited by 46
Wang, L., Davis, P. B., Kaelber, D. C., & Xu, R. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12669 · Cited by 46
Islam, M. A. (2023) · Infectious Medicine · doi:10.1016/j.imj.2023.08.005 · Cited by 46
SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review
Emrani, J., Ahmed, M., Jeffers-Francis, L. K., Teleha, J. C., Mowa, C. N., Newman, R. H., & Thomas, M. D. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.172 · Cited by 49
Spike protein of SARS-CoV-2 variants: a brief review and practical implications
Candido, K. L., Eich, C. R., de Fariña, L. O., Kadowaki, M. K., Silva, J. L. D. C., Maller, A., & Simão, R. D. C. G. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-022-00743-z · Cited by 46
Bigay, J., Grand, R. L., Martinon, F., & Maisonnasse, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932408 · Cited by 51
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations
Yan, Z., Yang, M., & Lai, C. (2021) · Vaccines · doi:10.3390/vaccines9101097 · Cited by 48
Chen, L., Qu, J., Kalyani, F. S., Zhang, Q., Fan, L., Fang, Y., Li, Y., & Xiang, C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04096-y · Cited by 47
Burnett, D. L., Jackson, K., Langley, D. B., Aggarwal, A., Stella, A. O., Johansen, M. D., Balachandran, H., Lenthall, H., Rouet, R., Walker, G. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.019 · Cited by 45
Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review
Garg, I., Sheikh, A. B., Pal, S., & Shekhar, R. (2022) · Infectious Disease Reports · doi:10.3390/idr14040057 · Cited by 47
Metadata
- Authors
- Hacisuleyman, E., Hale, C., Saito, Y., Blachere, N. E., Bergh, M., Conlon, E. G., Schaefer-Babajew, D. J., DaSilva, J., Muecksch, F., Gaebler, C., Lifton, R., Nussenzweig, M. C., Hatziioannou, T., Bieniasz, P. D., & Darnell, R. B.
- Affiliations
- Howard Hughes Medical Institute (US)
- From the Laboratory of Molecular Neuro-oncology (E.H., C.H., Y.S., N.E.B., M.B., E.G.C., R.B.D.), the Laboratory of Molecular Immunology (D.J.S.-B., C.G., M.C.N.), the Laboratory of Human Genetics and Genomics (R.L.), the Laboratory of Retrovirology (J.D., F.M., T.H., P.D.B.), and the Howard Hughes Medical Institute (M.C.N., P.D.B., R.B.D.), Rockefeller University, New York.
- Corresponding author
- Darnell, Robert B.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-10
- Volume
- 384
- Issue
- 23
- Pages
- 2212-2218
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8117968
- OpenAlex
- W3153636933
- Cited by
- 716
- References
- 11
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 42 · 2023: 102 · 2022: 298 · 2021: 239
- FWCI
- 54.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2 variants, breakthrough infection, COVID-19 vaccination, BNT162b2, mRNA-1273, E484K mutation, D614G mutation, viral genome sequencing, vaccine efficacy
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Aged, Antibodies, Viral, Female, Humans, Middle Aged, Mutation, Neutralization Tests, Phylogeny, Polymerase Chain Reaction, Sequence Analysis, RNA, Viral Load, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
